Mylan may have overcharged taxpayers as much as $1.27 billion over 10 years for its signature EpiPens, according to an analysis released Wednesday.
By Ike Swetlitz, STAT
The head of pharmaceutical company Mylan is defending the cost for life-saving EpiPens, signaling the company has no plans to lower prices despite a public outcry and questions from skeptical lawmakers.
By Mary Clare Jalonick, Associated Press
Following the public outcry over steep increases in price for an emergency allergy treatment, Hillary Clinton is pledging to better protect patients from such costs.
By Catherine Lucey, Associated Press
After news broke that the price of EpiPen injectors has skyrocketed, the allergy medicine’s maker, Mylan, announced its intention to offer a generic version of the product, to be sold at half the market price of the original. The New…
By PBS NewsHour
Identical to the original product -- a pre-filled syringe containing epinephrine, used for life-threatening allergic reactions -- the generic will cost $300 for two.
By Ike Swetlitz and Ed Silverman, STAT
Mylan’s “EpiPen4Schools” program, begun in August 2012, offers free or discounted EpiPens to schools.
Support Provided By: Learn more
Educate your inbox
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.